These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 29155026)

  • 1. Personalized nanomedicine for CNS diseases.
    Kaushik A; Jayant RD; Bhardwaj V; Nair M
    Drug Discov Today; 2018 May; 23(5):1007-1015. PubMed ID: 29155026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanotechnology-based drug delivery for central nervous system disorders.
    Nguyen TT; Dung Nguyen TT; Vo TK; Tran NM; Nguyen MK; Van Vo T; Van Vo G
    Biomed Pharmacother; 2021 Nov; 143():112117. PubMed ID: 34479020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of Therapeutic Nanoplatforms as a Potential Candidate for the Treatment of CNS Disorders: Challenges and Possibilities.
    Sa P; Singh P; Dilnawaz F; Sahoo SK
    Curr Pharm Des; 2022; 28(33):2742-2757. PubMed ID: 35909283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting specific cells in the brain with nanomedicines for CNS therapies.
    Zhang F; Lin YA; Kannan S; Kannan RM
    J Control Release; 2016 Oct; 240():212-226. PubMed ID: 26686078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug delivery across the blood-brain barrier: recent advances in the use of nanocarriers.
    Mulvihill JJ; Cunnane EM; Ross AM; Duskey JT; Tosi G; Grabrucker AM
    Nanomedicine (Lond); 2020 Jan; 15(2):205-214. PubMed ID: 31916480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanomedicine and its application in treatment of microglia-mediated neuroinflammation.
    Baby N; Patnala R; Ling EA; Dheen ST
    Curr Med Chem; 2014; 21(37):4215-26. PubMed ID: 25039775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential Use of Nanomedicine for Drug Delivery Across the Blood-Brain Barrier in Healthy and Diseased Brain.
    Ruozi B; Belletti D; Pederzoli F; Forni F; Vandelli MA; Tosi G
    CNS Neurol Disord Drug Targets; 2016; 15(9):1079-1091. PubMed ID: 27633786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic approaches of magnetic nanoparticles for the central nervous system.
    Dilnawaz F; Sahoo SK
    Drug Discov Today; 2015 Oct; 20(10):1256-64. PubMed ID: 26103617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BBB-targeting, protein-based nanomedicines for drug and nucleic acid delivery to the CNS.
    Peluffo H; Unzueta U; Negro-Demontel ML; Xu Z; Váquez E; Ferrer-Miralles N; Villaverde A
    Biotechnol Adv; 2015; 33(2):277-87. PubMed ID: 25698504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Nanomedicine-Based Therapeutics in the Treatment of CNS Disorders.
    Guo ZH; Khattak S; Rauf MA; Ansari MA; Alomary MN; Razak S; Yang CY; Wu DD; Ji XY
    Molecules; 2023 Jan; 28(3):. PubMed ID: 36770950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in nanomedicines for diagnosis of central nervous system disorders.
    Zhang X; Zhou J; Gu Z; Zhang H; Gong Q; Luo K
    Biomaterials; 2021 Feb; 269():120492. PubMed ID: 33153757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanomedicines for the Treatment of CNS Diseases.
    Reynolds JL; Mahato RI
    J Neuroimmune Pharmacol; 2017 Mar; 12(1):1-5. PubMed ID: 28150132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Getting drugs to the brain: advances and prospects of organic nanoparticle delivery systems for assisting drugs to cross the blood-brain barrier.
    Tan Q; Zhao S; Xu T; Wang Q; Lan M; Yan L; Chen X
    J Mater Chem B; 2022 Nov; 10(45):9314-9333. PubMed ID: 36349976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent Trends in Nanotechnology Toward CNS Diseases: Lipid-Based Nanoparticles and Exosomes for Targeted Therapeutic Delivery.
    Cardoso AM; Guedes JR; Cardoso AL; Morais C; Cunha P; Viegas AT; Costa R; Jurado A; Pedroso de Lima MC
    Int Rev Neurobiol; 2016; 130():1-40. PubMed ID: 27678173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood-brain barrier disruption in dementia: Nano-solutions as new treatment options.
    Cooper CG; Kafetzis KN; Patabendige A; Tagalakis AD
    Eur J Neurosci; 2024 Mar; 59(6):1359-1385. PubMed ID: 38154805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanotechnological advances for the delivery of CNS therapeutics.
    Wong HL; Wu XY; Bendayan R
    Adv Drug Deliv Rev; 2012 May; 64(7):686-700. PubMed ID: 22100125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of Nanomedicine to the CNS Diseases.
    Carradori D; Gaudin A; Brambilla D; Andrieux K
    Int Rev Neurobiol; 2016; 130():73-113. PubMed ID: 27678175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Research advances in brain-targeted nanoscale drug delivery system].
    Liu Y; Jiang C
    Yao Xue Xue Bao; 2013 Oct; 48(10):1532-43. PubMed ID: 24417079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging and nanomedicine for diagnosis and therapy in the central nervous system: report of the eleventh annual Blood-Brain Barrier Disruption Consortium meeting.
    Muldoon LL; Tratnyek PG; Jacobs PM; Doolittle ND; Christoforidis GA; Frank JA; Lindau M; Lockman PR; Manninger SP; Qiang Y; Spence AM; Stupp SI; Zhang M; Neuwelt EA
    AJNR Am J Neuroradiol; 2006 Mar; 27(3):715-21. PubMed ID: 16552023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanomedicine-based immunotherapy for central nervous system disorders.
    Hanif S; Muhammad P; Chesworth R; Rehman FU; Qian RJ; Zheng M; Shi BY
    Acta Pharmacol Sin; 2020 Jul; 41(7):936-953. PubMed ID: 32467570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.